EPIRUS Biopharmaceuticals, Inc. announced consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenue of $4,000. Loss from operations was $10,156,000 compared to $3,830,000 a year ago. Net loss was $10,400,000 compared to $7,771,000 a year ago. Basic and diluted loss per share was $0.80 compared to $32.79 a year ago.

For the year, the company reported revenue of $4,000. Loss from operations was $39,255,000 compared to $14,468,000 a year ago. Net loss was $41,844,000 compared to $20,795,000 a year ago. Basic and diluted loss per share was $6.81 compared to $88.26 a year ago.